» Articles » PMID: 33924103

Treatment Options for Motor and Non-Motor Symptoms of Parkinson's Disease

Overview
Journal Biomolecules
Publisher MDPI
Date 2021 Apr 30
PMID 33924103
Citations 62
Authors
Affiliations
Soon will be listed here.
Abstract

Parkinson's disease (PD) usually presents in older adults and typically has both motor and non-motor dysfunctions. PD is a progressive neurodegenerative disorder resulting from dopaminergic neuronal cell loss in the mid-brain substantia nigra pars compacta region. Outlined here is an integrative medicine and health strategy that highlights five treatment options for people with Parkinson's (PwP): rehabilitate, therapy, restorative, maintenance, and surgery. Rehabilitating begins following the diagnosis and throughout any additional treatment processes, especially vis-à-vis consulting with physical, occupational, and/or speech pathology therapist(s). Therapy uses daily administration of either the dopamine precursor levodopa (with carbidopa) or a dopamine agonist, compounds that preserve residual dopamine, and other specific motor/non-motor-related compounds. Restorative uses strenuous aerobic exercise programs that can be neuroprotective. Maintenance uses complementary and alternative medicine substances that potentially support and protect the brain microenvironment. Finally, surgery, including deep brain stimulation, is pursued when PwP fail to respond positively to other treatment options. There is currently no cure for PD. In conclusion, the best strategy for treating PD is to hope to slow disorder progression and strive to achieve stability with neuroprotection. The ultimate goal of any management program is to improve the quality-of-life for a person with Parkinson's disease.

Citing Articles

Drug utilization study of antiparkinsonian medication in Romania during 25 years.

Bucsa C, Bruhs D, Apan A, Francu E, Mogosan C, Iaru I Front Pharmacol. 2025; 16:1534344.

PMID: 39974739 PMC: 11835688. DOI: 10.3389/fphar.2025.1534344.


Analytical method for simultaneous quantification of levodopa and carbidopa in the injectable oleogel formulation by HPLC.

Nakmode D, Youssef S, Das S, Song Y, Garg S BMC Chem. 2025; 19(1):43.

PMID: 39962556 PMC: 11834227. DOI: 10.1186/s13065-025-01410-8.


Recent advances in nanotechnology for Parkinson's disease: diagnosis, treatment, and future perspectives.

Yadav V, Dhanasekaran S, Choudhary N, Nathiya D, Thakur V, Gupta R Front Med (Lausanne). 2025; 12:1535682.

PMID: 39911864 PMC: 11794224. DOI: 10.3389/fmed.2025.1535682.


Exploring glycolytic enzymes in disease: potential biomarkers and therapeutic targets in neurodegeneration, cancer and parasitic infections.

Rojas-Pirela M, Andrade-Alviarez D, Rojas V, Marcos M, Salete-Granado D, Chacon-Arnaude M Open Biol. 2025; 15(2):240239.

PMID: 39904372 PMC: 11793985. DOI: 10.1098/rsob.240239.


A novel muscle network approach for objective assessment and profiling of bulbar involvement in ALS.

Rong P, Heidrick L, Pattee G Front Neurosci. 2025; 18:1491997.

PMID: 39867453 PMC: 11759300. DOI: 10.3389/fnins.2024.1491997.


References
1.
Berganzo K, Tijero B, Gonzalez-Eizaguirre A, Somme J, Lezcano E, Gabilondo I . Motor and non-motor symptoms of Parkinson's disease and their impact on quality of life and on different clinical subgroups. Neurologia. 2014; 31(9):585-591. DOI: 10.1016/j.nrl.2014.10.010. View

2.
Farley B, Koshland G . Training BIG to move faster: the application of the speed-amplitude relation as a rehabilitation strategy for people with Parkinson's disease. Exp Brain Res. 2005; 167(3):462-7. DOI: 10.1007/s00221-005-0179-7. View

3.
COTZIAS G, PAPAVASILIOU P, GELLENE R . Modification of Parkinsonism--chronic treatment with L-dopa. N Engl J Med. 1969; 280(7):337-45. DOI: 10.1056/NEJM196902132800701. View

4.
Vink R . Magnesium in the CNS: recent advances and developments. Magnes Res. 2016; 29(3):95-101. DOI: 10.1684/mrh.2016.0408. View

5.
. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol. 2002; 59(12):1937-43. DOI: 10.1001/archneur.59.12.1937. View